MEDINOX (LONDON) LIMITEDActive

Company number 11149212Private limited companyIncorporated 2018

Key figures

−£1,151,987-4.8%
Net assets 2024/25
-1.5 m-1 m-500 k02020/212021/222023/242024/25

Like most small UK companies, MEDINOX (LONDON) LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m1.5 m2020/212021/222023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222023/242024/25
Cash at bank and in hand618,83122,77718,44942,063
Total assets1,250,381641,155811,232923,861
Total liabilities————
Net assets / total equity-843,879-1,129,051-1,099,250-1,151,987
Average number of employees4434

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

The principal activity of the company in the year under review was that of the trading of medical goods.

As described in the company's latest filed accounts.

Summary: MEDINOX (LONDON) LIMITED

Company

MEDINOX (LONDON) LIMITED is a private limited company registered with Companies House under company number 11149212. It was incorporated on 15 Jan 2018. Its status is active. The registered office is in Walthamstow (E17). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460), non-specialised wholesale trade (46900).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Jan 2025); the company files small company accounts (filleted). Net assets were −£1,151,987, down 4.8% on the previous year. Cash at bank and in hand was £42,063. The company had an average of 4 employees. Figures are available for 4 financial years (2020/21–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Oct 2026. The next confirmation statement is due by 2 Jan 2027.